JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yonehara, N.
Right arrow Articles by Clouet, D. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yonehara, N.
Right arrow Articles by Clouet, D. H.

Effects of delta and mu opiopeptides on the turnover and release of dopamine in rat striatum

N Yonehara and DH Clouet

Two mu and two delta opiopeptides were administered intracisternally and morphine was administered systemically to rats. The level of dopamine (DA) and its catabolites, homovanillic acid, dihydroxyphenylacetic acid and 3-methoxytramine were measured by high- pressure liquid chromatography with electrical detector in rat striatum to determine: 1) whether opioids alter the release of DA from striatal neuron (which would be indicated by changes in the level of 3- methoxytramine, the extraneuronal catabolite) and 2) whether delta or mu ligands have a greater effect on DA turnover. We found that the levels of 3-methoxytramine did not rise in response to the administration of any opiopeptide or morphine. However, mu opiopeptides produced a small but significant decrease in these levels, indicating that there was no increase, but instead a slight decrease in DA release. The delta opiopeptides produced larger increases in homovanillic acid and dihydroxyphenylacetic acid than the mu ligands, indicating that delta ligands are more effective on an equidose basis in increasing the turnover of striatal DA. The opiopeptides were also tested for pharmacological activity at the same dose (3 micrograms/rat). All four peptides were effective in reducing locomotor activity and producing analgesia. One peptide, Tyr-d-Ala-Gly-N-Mephe- Met-O-ol, also produced catalepsy. There was no segregation of these two behavioral responses according to ligand specificity. Morphine acted like a delta ligand in affecting DA turnover.

Volume 231, Issue 1, pp. 38-42, 10/01/1984
Copyright © 1984 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 Pharmacol. Rev.Home page
J. Fichna, A. Janecka, J. Costentin, and J.-C. Do Rego
The Endomorphin System and Its Evolving Neurophysiological Role
Pharmacol. Rev., March 1, 2007; 59(1): 88 - 123.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
A. Verma and S. K. Kulkarni
Modulatory role of D-1 and D-2 dopamine receptor subtypes in nociception in mice
J Psychopharmacol, January 1, 1993; 7(3): 270 - 275.
[Abstract] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1984 by the American Society for Pharmacology and Experimental Therapeutics.